* LIPITRIN 40/10 (Simvastatin + Ezetimibe) 7 Tablets. Lipid Lowering Drug.* Indications:  – Primary Hypercholesterolemia:  Lipitrin is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density  lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), & non-high-density lipoprotein cholesterol  (non-HDL-C), & to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial &  non-familial) hypercholesterolemia or mixed hyperlipidemia.  – Homozygous Familial Hypercholesterolemia (HoFH): Lipitrin is indicated for the reduction of elevated total-C levels in patients  with HoFH. Patients may also receive adjunctive treatments (e.g. LDL apheresis).* Dosage & Administration:  – The patient should be placed on a standard cholesterol-lowering diet before receiving Lipitrin & should continue on this diet  treatment with Lipitrin.  – The dosage should be individualized according to the baseline LDL-C level, the recommended goal of therapy, & response.  – Lipitrin should be taken as a single daily dose in the evening, with or without food.  – The recommended usual starting dose is 20/10 mg/day.  – Initiation of therapy with 10/10 mg/day may be considered for patients requiring less aggressive LDL-C reductions.  – Patients who require a larger reduction in LDL-C (greater than 55%) may be started at 40/10 mg/day.  – After initiation of therapy, Lipid levels may be analyzed after 2 or more weeks & dosage adjusted, if needed.  – Dosage in Patients with Homozygous Familial Hypercholesterolemia: The recommended dosage is Lipitrin 40/10 mg/day  or 80/10 mg/day in the evening. Lipitrin should be used as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis)  in these patients or if such treatments are unavailable.  – Use in the elderly: No dosage adjustment is required for elderly patients.* Store below 30 degrees C.* Produced by: Chemipharm Pharmaceutical Industries S.A.E. – Egypt.